Neoclarityn

How to order Neoclarityn

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Neoclarityn on Prescriptsy

Neoclarityn is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Neoclarityn is a prescription antihistamine containing desloratadine 5 mg, manufactured by MSD (Merck Sharp and Dohme).

Desloratadine is a second-generation, non-sedating antihistamine used to relieve the symptoms of allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives of unknown cause).

Neoclarityn is classified as a prescription-only medicine (POM) in the United Kingdom and is available on the NHS.

Allergic conditions are among the most common reasons for GP consultations in the UK.

Allergic rhinitis alone affects an estimated 10 to 30 per cent of the adult population and up to 40 per cent of children.

Chronic urticaria, defined as hives occurring on most days for 6 weeks or more, affects approximately 1 per cent of the population at any given time and can cause significant distress and impairment of quality of life.

Non-sedating antihistamines are the first-line treatment for both conditions.

This page provides a comprehensive clinical overview of Neoclarityn, including how it works, dosage guidance, side effects, important safety information, and how to obtain a prescription in the United Kingdom.

Important safety information about Neoclarityn

• Neoclarityn is a prescription-only medicine. Use it only as directed by your prescriber.
• Do not take Neoclarityn if you are allergic to desloratadine or loratadine.
• Neoclarityn is classified as non-sedating, but a small number of patients may experience mild drowsiness.
• At recommended doses, desloratadine does not impair driving ability or interact significantly with alcohol.
• If you have severe liver disease, discuss with your prescriber before taking Neoclarityn.

Understanding antihistamines and allergic disease

Histamine is a chemical released by mast cells and basophils during an allergic reaction.

When histamine binds to H1 receptors in the nose, eyes, skin, and airways, it triggers the familiar symptoms of allergy: sneezing, itching, rhinorrhoea (runny nose), nasal congestion, watery eyes, and urticarial wheals (hives).

Antihistamines work by blocking H1 receptors, preventing histamine from exerting its effects on target tissues.

First-generation antihistamines (chlorphenamine, promethazine, hydroxyzine) cross the blood-brain barrier readily and cause significant sedation, impaired concentration, and anticholinergic effects (dry mouth, urinary retention, blurred vision).

They have a short duration of action and require multiple daily doses.

Second-generation antihistamines (cetirizine, loratadine, fexofenadine, desloratadine, bilastine, rupatadine) were developed to provide effective H1 blockade without significant CNS penetration.

They are longer-acting, allowing once-daily dosing, and have a much lower incidence of sedation and anticholinergic effects.

NICE, the BSACI, and the EAACI all recommend second-generation antihistamines as first-line pharmacotherapy for allergic rhinitis and chronic urticaria.

How Neoclarityn works: mechanism of action

Desloratadine is a selective, long-acting H1 receptor antagonist.

It is the primary active metabolite of loratadine, formed by hepatic first-pass metabolism via the cytochrome P450 enzyme system (predominantly CYP3A4 and CYP2D6).

Unlike loratadine, desloratadine does not require hepatic activation, which means its efficacy is less dependent on individual variations in liver enzyme activity.

This gives desloratadine a more predictable pharmacokinetic profile across different patient populations.

At the molecular level, desloratadine acts as an inverse agonist at the H1 receptor, meaning it not only blocks histamine from binding but also reduces the constitutive (baseline) activity of the receptor.

This is thought to contribute to its anti-inflammatory properties beyond simple histamine blockade.

In vitro studies have demonstrated that desloratadine inhibits the release of several pro-inflammatory mediators from human mast cells and basophils, including histamine, tryptase, prostaglandin D2, and leukotriene C4.

It also inhibits the release of pro-inflammatory cytokines (IL-4, IL-6, IL-8, IL-13) and reduces the expression of adhesion molecules on endothelial cells, which may help to reduce the recruitment of inflammatory cells to sites of allergic inflammation.

The clinical relevance of these additional anti-inflammatory properties is not fully established, but they may contribute to the sustained symptom relief observed with desloratadine in clinical trials, particularly in chronic urticaria where the inflammatory component extends beyond simple histamine release.

Clinical evidence and UK prescribing guidance

The efficacy of desloratadine has been demonstrated in numerous randomised, double-blind, placebo-controlled trials.

In seasonal allergic rhinitis, desloratadine 5 mg once daily significantly reduced total symptom scores (nasal congestion, rhinorrhoea, sneezing, itching, and ocular symptoms) compared with placebo, with onset of action within 2 hours of the first dose and sustained efficacy over 24 hours.

In perennial allergic rhinitis, desloratadine provided significant relief of nasal and non-nasal symptoms over 4 weeks of treatment.

In chronic idiopathic urticaria, desloratadine 5 mg once daily significantly reduced pruritus (itching), number of wheals, and overall interference with sleep and daily activities compared with placebo.

NICE recommends non-sedating antihistamines as first-line treatment for allergic rhinitis, with intranasal corticosteroids reserved for patients with moderate to severe symptoms or predominant nasal congestion.

The BSACI guideline on the management of allergic and non-allergic rhinitis recommends second-generation oral antihistamines for mild to moderate symptoms, noting that they are effective for sneezing, itching, rhinorrhoea, and eye symptoms but less effective for nasal congestion.

For chronic urticaria, the BSACI and EAACI guidelines recommend a stepwise approach: standard-dose non-sedating antihistamine as first-line treatment, with up-dosing (up to four times the standard dose) as second-line treatment before considering add-on therapies such as montelukast, ciclosporin, or omalizumab.

Neoclarityn compared with other antihistamines

Several second-generation antihistamines are available in the UK.

Cetirizine (10 mg once daily) is widely available over the counter and is effective but causes mild sedation in approximately 10 per cent of users.

Loratadine (10 mg once daily) is the parent compound of desloratadine and is available without prescription; it is truly non-sedating in most patients but requires hepatic activation, which may lead to variable efficacy in some individuals.

Fexofenadine (120 mg or 180 mg once daily) is available over the counter for hay fever (120 mg) and on prescription for urticaria (180 mg); it is well-tolerated and non-sedating.

Bilastine (20 mg once daily) is a newer non-sedating antihistamine available on prescription, taken on an empty stomach.

Rupatadine (10 mg once daily) is available on prescription and has additional anti-platelet activating factor (anti-PAF) activity.

Head-to-head comparisons between second-generation antihistamines have generally shown similar overall efficacy, though individual patients may respond better to one agent than another.

If one antihistamine is not effective or causes side effects, switching to a different one is reasonable and recommended by guidelines.

For chronic urticaria, guidelines specifically recommend trying at least one up-dosed antihistamine before adding alternative therapies.

Dosage and administration

Take one 5 mg Neoclarityn tablet once daily, with or without food. Swallow whole with water.

The tablet can be taken at any time of day but taking it at a consistent time each day helps maintain steady plasma levels and consistent symptom control.

For children aged 6 to 11 years, the oral solution formulation should be used at a dose of 2.5 mg (5 ml) once daily.

For children aged 1 to 5 years, the dose is 1.25 mg (2.5 ml) once daily.

For chronic urticaria that does not respond to the standard dose, specialist guidelines (BSACI, EAACI) support up-dosing to 10 mg (two tablets) or 20 mg (four tablets) once daily.

This is an off-label use of desloratadine but is well-supported by clinical evidence. Discuss with your prescriber before adjusting the dose.

No dose adjustment is required for renal impairment or for elderly patients.

Side effects of Neoclarityn

Common side effects

In clinical trials, the overall incidence of adverse effects with desloratadine 5 mg was comparable to placebo.

The most commonly reported side effects in adults are headache, dry mouth, and fatigue. These are typically mild and transient.

In children, commonly reported side effects include diarrhoea, pyrexia (fever), and insomnia.

Uncommon and rare side effects

Uncommon side effects include dizziness, somnolence, tachycardia (fast heartbeat), abdominal pain, nausea, vomiting, and raised liver enzymes.

Rare side effects include myalgia, hypersensitivity reactions (rash, pruritus, urticaria, angioedema, anaphylaxis), and very rarely hepatitis.

Post-marketing surveillance has identified rare reports of psychomotor hyperactivity and seizures, though a causal relationship has not been confirmed.

Effect on driving and cognitive function

At the recommended 5 mg dose, desloratadine does not impair psychomotor performance, reaction time, or driving ability in clinical studies. It does not potentiate the effects of alcohol.

These properties make it suitable for patients who need to drive, operate machinery, or maintain concentration during the day.

However, individual responses may vary, and patients should exercise caution until they are familiar with how the medicine affects them.

When to seek urgent medical advice

Seek immediate medical help if you experience signs of a severe allergic reaction: swelling of the face, lips, tongue, or throat; difficulty breathing or swallowing; widespread skin rash or hives.

Call 999 in an emergency. Contact your GP or call NHS 111 if you develop palpitations, persistent nausea, yellowing of the skin or eyes, or dark urine.

Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Contraindications

Neoclarityn is contraindicated in patients with known hypersensitivity to desloratadine, loratadine, or any excipient in the formulation. Patients who have experienced allergic reactions to loratadine should not take desloratadine due to structural similarity and potential cross-reactivity.

Special precautions

Use with caution in patients with severe hepatic impairment, as the clearance of desloratadine may be reduced.

Patients with epilepsy or a history of seizures should discuss treatment with their prescriber, as very rare cases of seizures have been reported.

The oral solution formulation contains sorbitol and should not be used in patients with hereditary fructose intolerance.

Drug interactions

No clinically significant drug interactions have been identified in controlled studies with erythromycin, ketoconazole, azithromycin, fluoxetine, or cimetidine. Desloratadine does not interact significantly with grapefruit juice.

There is no significant potentiation of the CNS effects of alcohol at recommended doses. As with all medicines, inform your prescriber and pharmacist of everything you are taking.

Pregnancy and breastfeeding

Neoclarityn should be used during pregnancy only if the expected benefit justifies any potential risk. Animal studies have not demonstrated teratogenic effects.

There are no adequate controlled human studies. Desloratadine is excreted in breast milk. If you are breastfeeding, discuss the risks and benefits with your prescriber.

Loratadine (the parent compound) is generally considered compatible with breastfeeding by many guidelines, but prescriber guidance should be sought for the branded desloratadine product.

How to get Neoclarityn in the UK

Neoclarityn is a prescription-only medicine. You can obtain a prescription from your GP or through an authorised online prescriber registered with the GPhC.

The standard NHS prescription charge of 9.90 pounds applies in England; prescriptions are free in Scotland, Wales, and Northern Ireland.

If you would like a non-prescription antihistamine, cetirizine, loratadine, and fexofenadine (120 mg) are available over the counter from pharmacies.

Your pharmacist can help you choose an appropriate product.

Lifestyle advice for managing allergies and urticaria

Identifying and avoiding allergen triggers is an important part of managing allergic rhinitis. Keep a symptom diary to identify patterns.

For hay fever, check pollen forecasts and take precautions on high-count days.

For chronic urticaria, avoiding known triggers (heat, tight clothing, stress, alcohol, aspirin, and NSAIDs) may help reduce flare-ups.

Wearing loose, cool clothing and using emollients can soothe itchy skin. If symptoms are persistent or severe, ask your GP for referral to an allergist or dermatologist.

Sources

• Neoclarityn Tablets, Summary of Product Characteristics (EMC)
• Desloratadine, British National Formulary (BNF)
• Allergic rhinitis, NICE Clinical Knowledge Summary
• Antihistamines, NHS
• MHRA Yellow Card Scheme